Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aashis Thapa

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|July 27, 2024
MERTK Inhibition as a Targeted Novel Cancer TherapyK M Tanim, Alisha Holtzhausen, Aashis Thapa, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AMLJames M Kelvin, Juhi Jain, Aashis Thapa, et al.
Pharmaceutical Research|September 13, 2023
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AMLJames M Kelvin, Juhi Jain, Aashis Thapa, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 5, 2023
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemiaJames M Kelvin, Madison L Chimenti, Dan Y Zhang, et al.
Nature|October 19, 2018
Functional genomic landscape of acute myeloid leukaemiaJeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell|July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaDaniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|July 27, 2024
MERTK Inhibition as a Targeted Novel Cancer TherapyK M Tanim, Alisha Holtzhausen, Aashis Thapa, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AMLJames M Kelvin, Juhi Jain, Aashis Thapa, et al.
Pharmaceutical Research|September 13, 2023
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AMLJames M Kelvin, Juhi Jain, Aashis Thapa, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 5, 2023
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemiaJames M Kelvin, Madison L Chimenti, Dan Y Zhang, et al.
Nature|October 19, 2018
Functional genomic landscape of acute myeloid leukaemiaJeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell|July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaDaniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Pageof 1